JP2015520768A5 - - Google Patents

Download PDF

Info

Publication number
JP2015520768A5
JP2015520768A5 JP2015514149A JP2015514149A JP2015520768A5 JP 2015520768 A5 JP2015520768 A5 JP 2015520768A5 JP 2015514149 A JP2015514149 A JP 2015514149A JP 2015514149 A JP2015514149 A JP 2015514149A JP 2015520768 A5 JP2015520768 A5 JP 2015520768A5
Authority
JP
Japan
Prior art keywords
fragment
antibody
composition
ccl2
ccl2 antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015514149A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015520768A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/042196 external-priority patent/WO2013177264A1/en
Publication of JP2015520768A publication Critical patent/JP2015520768A/ja
Publication of JP2015520768A5 publication Critical patent/JP2015520768A5/ja
Pending legal-status Critical Current

Links

JP2015514149A 2012-05-22 2013-05-22 強皮症の処置用の抗−ccl2抗体 Pending JP2015520768A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261650149P 2012-05-22 2012-05-22
US61/650,149 2012-05-22
PCT/US2013/042196 WO2013177264A1 (en) 2012-05-22 2013-05-22 Anti-ccl2 antibodies for treatment of scleroderma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017151434A Division JP2017193588A (ja) 2012-05-22 2017-08-04 強皮症の処置用の抗−ccl2抗体

Publications (2)

Publication Number Publication Date
JP2015520768A JP2015520768A (ja) 2015-07-23
JP2015520768A5 true JP2015520768A5 (https=) 2016-06-30

Family

ID=49624311

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015514149A Pending JP2015520768A (ja) 2012-05-22 2013-05-22 強皮症の処置用の抗−ccl2抗体
JP2017151434A Pending JP2017193588A (ja) 2012-05-22 2017-08-04 強皮症の処置用の抗−ccl2抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017151434A Pending JP2017193588A (ja) 2012-05-22 2017-08-04 強皮症の処置用の抗−ccl2抗体

Country Status (12)

Country Link
US (3) US20150158942A1 (https=)
EP (1) EP2852411A4 (https=)
JP (2) JP2015520768A (https=)
CN (2) CN104487091A (https=)
AU (2) AU2013266340A1 (https=)
BR (1) BR112014029013A2 (https=)
CA (1) CA2874031A1 (https=)
EA (1) EA201491957A1 (https=)
HK (2) HK1208825A1 (https=)
IN (1) IN2014DN09951A (https=)
MX (2) MX2014014290A (https=)
WO (1) WO2013177264A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2014268316B2 (en) * 2013-05-23 2019-10-10 Takeda Pharmaceutical Company Limited Anti-CCL2 and anti-LOXL2 combination therapy for treatment of scleroderma
ES2795727T3 (es) * 2014-01-15 2020-11-24 Medimmune Llc Anticuerpos específicos del vrs y partes funcionales de los mismos

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003531588A (ja) * 2000-04-11 2003-10-28 ジェネンテック・インコーポレーテッド 多価抗体とその用途
AR037456A1 (es) * 2001-11-30 2004-11-10 Biogen Inc Anticuerpos contra proteinas quimiotacticas monocitarias
EP1515743A2 (en) * 2002-04-10 2005-03-23 Applied Research Systems ARS Holding N.V. Use of osteoprotegerin for the prevention and/or treatment of fibrosis/sclerosis
PE20061444A1 (es) * 2005-05-19 2007-01-15 Centocor Inc Anticuerpo anti-mcp-1, composiciones, metodos y usos
US8114964B2 (en) * 2005-05-19 2012-02-14 Centocor, Inc. Anti-MCP-1 antibodies, compositions, methods and uses
US20080076120A1 (en) * 2006-09-14 2008-03-27 Millennium Pharmaceuticals, Inc. Methods for the identification, evaluation and treatment of patients having CC-Chemokine receptor 2 (CCR-2) mediated disorders
CA2665808A1 (en) * 2006-10-05 2008-05-22 Centocor Ortho Biotech Inc. Ccr2 antagonists for treatment of fibrosis

Similar Documents

Publication Publication Date Title
JP2017503820A5 (https=)
JP2017501167A5 (https=)
JP2017507652A5 (https=)
JP2020099324A5 (https=)
JP2017534577A5 (https=)
JP2018508483A5 (https=)
JP2019515008A5 (https=)
JP2016529255A5 (https=)
EA201490957A1 (ru) Лечение гематологических злокачественных заболеваний с помощью анти-cxcr4 антитела
JP2014533279A5 (https=)
RU2018129874A (ru) Антитела против фактора свертывания xi
JP2009518441A5 (https=)
FI3799885T3 (fi) Lymfosyyttien estoreittien neutralointi
JP2011184466A5 (https=)
JP2017537090A5 (https=)
RU2018131237A (ru) Способы лечения атопического дерматита с помощью антагониста il-4r
JP2017501157A5 (https=)
JP2017524715A5 (https=)
JP2022512750A5 (https=)
UA118453C2 (uk) Спосіб лікування пухлин у пацієнта
JP2014511179A5 (https=)
JP2017500057A5 (https=)
JP2016509585A5 (https=)
EA201490622A1 (ru) Агенты, связывающие фактор роста эндотелия сосудов (vegf)/дельта-подобный лиганд (dll4), и их применение
RU2014143785A (ru) Фармацевтическая композиция для лечения и/или предотвращения рака печени